v3.25.4
Equity (Tables)
 6 Months Ended
Dec. 31, 2025
Disclosure of classes of share capital [abstract]  
Schedule of Share Capital Share capital
As of December 31,
2025202420252024
Shares No. (U.S. dollars, in thousands)
Contributed equity
(i)Share capital
Ordinary shares1,290,302,1871,154,023,9281,519,456 1,320,207 
Less: Treasury Shares(1,787,239)(1,579,499)— — 
Total Contributed Equity1,288,514,9481,152,444,4291,519,456 1,320,207 
Summary of Movements in Ordinary Share Capital Movements in ordinary share capital
Six Months Ended
December 31, 		Six Months Ended
December 31,
2025202420252024
Shares No.(U.S. dollars, in thousands)
Opening balance1,279,967,1871,141,784,1141,508,846 1,310,813 
Issues of ordinary shares during the period
Exercise of share options(1)
——3,994 1,341 
Transfer to employee share trust(1)
10,335,0007,200,000— — 
Placement of shares under a share placement agreement(2)
—5,039,8141,557 1,000 
Transaction costs arising on share issue——(114)(110)
Total contributions of equity during the period10,335,00012,239,8145,4372,231
Unissued ordinary shares during the period
Placement of shares under a share
   placement agreement(2)
——— (1,000)
Exercise of warrants(3)
——— 4,550 
Total contributions of unissued equity during the period——— 3,550 
Total contributions of equity
   during the period
10,335,00012,239,8145,437 5,781 
Share options reserve transferred to equity on exercise of options——5,173 3,613 
Ending balance1,290,302,1871,154,023,9281,519,456 1,320,207
(1)Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. Unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee.
(2)
In March 2024, Dr. Eric Rose, the Company's Chief Medical Offer and a director of Mesoblast, subscribed for 5,039,814 shares in Mesoblast Limited at A$0.30 per share, subject to shareholder approval which was received in November 2024. The shares remained in unissued capital until the shares were issued in December 2024.
(3)
On December 31, 2024, Oaktree exercised 188,122 ADS warrants that were issued in December 2022. The Group received $1.4 million of proceeds in relation to the exercise price of the warrants at US$7.24 per ADS, which was recognized within cash and cash equivalents in December 2024. On the exercise date of December 31, 2024, the fair value of $3.2 million relating to the warrants exercised and the exercise price of $1.3 million were recognized as unissued capital within the equity statement and remained as unissued capital until the shares were formally issued. On January 3, 2025, the Group formally issued 1,881,220 ordinary shares to Oaktree in relation to the exercise of these ADS warrants.
Summary of Movements of Shares in Share Trust Movements of shares in share trust
Six Months Ended
December 31, 		Six Months Ended
December 31,
2025202420252024
Shares No. (U.S. dollars, in thousands)
Opening balance32,389542,903— — 
Movement of shares in share trust
Transfer to employee share trust(1)
10,335,0007,200,000— — 
Exercise of share options(1)
(8,580,150)(6,163,404)— — 
Ending balance1,787,2391,579,499— — 
(1)Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. Unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee.
Summary of Warrant Reserves Warrant reserve
(in U.S. dollars, in thousands)As of
December 31,		As of
June 30,
Warrant reserve20252025
Opening balance12,969 12,969 
Movement during the period— — 
Closing Balance12,969 12,969